How Muscles May Help Keep Alzheimer’s Memory Loss at Bay

For decades, nearly every experimental medicine has targeted the brain directly. A growing area of research now indicates that muscles in the arms and legs could affect how long memory remains intact, even after the usual indicators of Alzheimer’s disease have appeared.

Muscles sending messages to the brain

Skeletal muscle was once regarded simply as the body’s engine: it contracts and enables movement, nothing more. That understanding is changing. Muscles also act as an endocrine organ, releasing signalling molecules into the bloodstream whenever they contract.

These molecules, known as myokines, travel well beyond the muscle where they originate. Their destinations include the liver, fatty tissue, the immune system and the brain.

A key protein in this research is cathepsin B, which generally increases following physical activity. Earlier studies in animals and people have associated higher cathepsin B levels with clearer thinking and better learning.

Exercise makes muscles speak a chemical language, and parts of that language seem to promote learning, memory and brain plasticity.

Plasticity is the brain’s capacity to adjust: it can reinforce or weaken links between neurons and create new connections. This mechanism supports the creation of new memories and the long-term retention of skills.

Testing a radical idea in an Alzheimer’s model

Researchers set out to test the concept in an extreme way. Rather than directing treatments at amyloid plaques in the brain - the sticky deposits characteristic of Alzheimer’s disease - they sought to amplify the messages produced by muscle itself.

They worked with mice genetically modified to develop Alzheimer’s-like changes in the brain and age-related memory difficulties. Scientists introduced genetic instructions into the muscles of some mice with a viral vector. Acting as a miniature delivery vehicle, the vector instructed muscle cells to produce additional cathepsin B.

Importantly, the virus was engineered to act only on muscle tissue. The researchers did not manipulate the brain directly.

Six months later: the brain looks damaged, the memory less so

The contrast between treated and untreated mice was pronounced after six months. Mice whose muscles produced more cathepsin B did much better in spatial-memory tests. In certain assessments, their learning came close to that of healthy mice of the same age without Alzheimer’s-like disease.

The team then examined the hippocampus, the seahorse-shaped brain area that is essential for making new memories. In untreated mice with the Alzheimer’s model, the creation of new hippocampal neurons - called neurogenesis - normally falls sharply. That reduction was largely reversed in the treated animals.

Despite the brain still showing disease markers, the machinery for making new neurons and flexible synapses had switched back on.

Protein patterns also changed in the brain, muscles and blood. In treated mice, profiles of protein expression became more similar to those in healthy animals, indicating a wider resetting of biological processes associated with memory and cell repair.

A route that bypasses classic Alzheimer’s targets

One of the most notable results concerned what remained unchanged. Months of treatment did not remove the classic features of the disease. Amyloid deposits were still present, and brain inflammation could still be detected.

Nevertheless, behaviour improved. This disconnect challenges the idea that amyloid must be cleared in order to preserve memory.

Instead, cathepsin B seems to alter the brain’s response to injury. It increases proteins involved in synaptic plasticity, protein production and neurogenesis. Put simply, it may enable the brain to compensate for damage rather than eliminate it.

A double-edged molecule

The findings are not simple. Raising cathepsin B in healthy mice without evidence of Alzheimer’s-like disease produced a different effect: these animals developed memory problems.

The same molecule that supports a vulnerable brain may disrupt a healthy one when pushed too far.

This difference implies that cathepsin B is a helper whose effects depend on context, rather than a cognitive enhancer that works universally. It could be beneficial only when brain circuits are already under pressure and harmful when those circuits are working normally.

What this could mean for future Alzheimer’s treatments

This research contributes to a broader change in Alzheimer’s research: considering the body as a connected system rather than viewing the brain in isolation. Messages from muscle, fatty tissue, the gut and immune cells may all influence how well the brain withstands ageing.

Focusing on muscle instead of neurons could offer several advantages in drug development. Muscle is easier to access and biopsy, and it is less fragile than brain tissue. Treatments might involve muscle injections or whole-body therapies that selectively increase particular myokines.

Potential approaches being considered include:

• Medicines that safely raise beneficial myokines such as cathepsin B only when required
• Exercise-mimicking compounds that activate muscle signalling without demanding workouts
• Gene therapies intended to fine-tune muscle-to-brain communication in people at high risk
• Personalised exercise plans informed by blood tests measuring myokine levels

Researchers also emphasise that findings in mice take time to translate into human treatments. Dosage, long-term safety and the possibility of cognitive side effects in healthy people all require careful investigation.

Where exercise fits into the picture

The results provide further biological support for advice neurologists have given for years: remaining physically active generally benefits brain health. Regular activity causes muscles to release a mixture of myokines, not merely cathepsin B, which appear to support neurons and blood vessels.

Different activities may generate different combinations of these signals. Aerobic activities, including brisk walking, cycling and swimming, are often associated with improved circulation and increased levels of certain growth factors. Strength training engages large muscle groups and may alter how muscles store and use energy.

Type of activity	Typical effect on body	Relevance to brain research
Aerobic exercise	Increases heart rate and circulation	Associated with greater blood flow in the brain and myokines linked to neurogenesis
Strength training	Builds and maintains muscle mass	Supports greater muscle “endocrine” output over time
Light daily movement	Limits extended sedentary periods	May deliver frequent, smaller bursts of muscle-derived signals

For those concerned about their dementia risk, researchers often advise combining cardiovascular exercise, strength work and balance exercises with good sleep habits, social interaction and mental challenges, such as acquiring new skills or learning languages. Each element affects different biological mechanisms that together influence brain resilience.

Key concepts behind the muscle–brain link

Some terminology used in this research may seem abstract. Two concepts are particularly important to this muscle-focused approach to Alzheimer’s disease.

Myokines: Small proteins that muscle cells release when they contract. They can affect appetite, inflammation, metabolism and brain function. Cathepsin B is one among many; others, including irisin, have also been linked with cognitive benefits in animals.

Neurogenesis: The formation of new neurons from stem-like cells, occurring mainly in the adult hippocampus. Although it happens on a modest scale compared with early life, these new cells appear to aid adaptable learning and mood regulation. Exercise, stress, diet and inflammation can each promote or inhibit this process.

A future clinical appointment illustrates how this could work. Someone in their late fifties with a strong family history of Alzheimer’s might one day have detailed blood tests for myokines and other peripheral markers alongside a brain scan. Rather than receiving one medicine aimed at the brain, they could leave with a combined plan: an individual exercise programme, possibly a muscle-focused treatment, and routine monitoring of changes in both muscle signals and memory-test results.

There are also risks. Excessively stimulating pathways such as cathepsin B in people without neurodegeneration could damage memory or affect other organs. Unequal availability of gene therapies or costly biologic medicines might deepen existing health inequalities. Nor would a muscle-based method remove the need to address established brain changes in later-stage disease.

Still, the central message is unexpectedly encouraging: our memory’s future may not be determined solely by the brain. Muscle strength and activity, along with the chemical messages muscles release, may form part of a wider strategy to hold Alzheimer’s at bay for longer.